Objectives: The population pharmacokinetic (popPK) characteristics of total mycophenolic acid (tMPA) have been investigated in various ethnic populations. However, investigations of popPK of unbound MPA (uMPA) are few. Thus, a popPK analysis was performed to: (1) characterize the PK of uMPA and tMPA and its 7-Omycophenolic acid glucuronide (MPAG) metabolite in kidney transplant patients cotreated with cyclosporine (CsA), and (2) identify the clinically significant covariates that explain variability in the dose-exposure relationship.
Objectives: The population pharmacokinetic (popPK) characteristics of total mycophenolic acid (tMPA) have been investigated in various ethnic populations. However, investigations of popPK of unbound MPA (uMPA) are few. Thus, a popPK analysis was performed to: (1) characterize the PK of uMPA and tMPA and its 7-Omycophenolic acid glucuronide (MPAG) metabolite in kidney transplant patients cotreated with cyclosporine (CsA), and (2) identify the clinically significant covariates that explain variability in the dose-exposure relationship.
Methods: A total of 740 uMPA, 741 tMPA, and 734 total MPAG (tMPAG) concentrationtime data from 58 Chinese kidney transplant patients receiving MPA in combination with CsA were analyzed using NONMEM ® software with the stochastic approximation expectation maximization (SAEM) followed by the important sampling (IMP) method. The influence of covariates was tested using a stepwise procedure.
Results: The PK of uMPA and unbound MPAG (uMPAG) were characterized by a twoand one-compartment model with first-order elimination, respectively. A linear protein binding model was used to link uMPA and tMPA. Apparent clearance (CL/F) and central volume of distribution (V C /F) of uMPA (CL uMPA /F and V CuMPA /F, respectively) and protein binding rate constant (k B ) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively. For uMPAG, the population values (RSE) of CL/F (CL uMPAG ) and V C /F (V CuMPAG /F) were 5.71 L/h (4.4%) and 29.9 L (7.7%), respectively. Between-subject variability (BSVs) on CL uMPA /F, V CuMPA /F, CL uMPAG /F, and V CuMPAG /F were 51.0, 80.0, 31.8 and 48.4%, respectively, whereas residual unexplained variability (RUVs) for uMPA, tMPA, and uMPAG were 47.0, 45.9, and 22.0%, respectively. Significant relationships were found between k B and serum albumin (ALB) and between CL uMPAG /F and glomerular filtration rate (GFR). Additionally, model-based simulation showed that changes in ALB concentrations substantially affected tMPA but not uMPA exposure.
INTRODUCTION
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is the predominant antimetabolite immunosuppressant used as a cotherapy with tacrolimus (TAC) or cyclosporine (CsA) to prevent graft rejection after solid organ transplantation (Hart et al., 2018; Hart et al., 2019) . MMF is extensively absorbed and rapidly hydrolyzed to the active component MPA after oral administration. The majority of MPA is metabolized to the pharmacologically inactive 7-Omycophenolic acid glucuronide (MPAG), whereas a lower fraction is metabolized to the active acyl-glucuronide mycophenolic acid (AcMPAG) (Bullingham et al., 1998; Kiang and Ensom, 2016) . MPA and MPAG are reported to be 97 and 82% bound to serum albumin (ALB), respectively at clinically relevant concentrations (Bullingham et al., 1998) . MPAG also undergoes enterohepatic circulation (EHC) through biliary excretion, followed by intestinal deglucuronidation and reabsorption as MPA in the colon. This process contributes to approximately 40% (range: 10-60%) of the area under the concentration-time curve (AUC) of MPA and causes multiple peaks in the concentration-time profile (Staatz and Tett, 2007) . Most absorbed MMF is eliminated through the kidney as MPAG (Staatz and Tett, 2007) .
MPA has a narrow therapeutic window and it is recommended to maintain a 12-h dosing interval exposure (AUC 0-12h ) between 30 and 60 mg·h/L during the early posttransplantation period (Shaw et al., 2001; van Gelder et al., 2006; Kuypers et al., 2010; Le Meur et al., 2011) . Under-exposure is associated with an increased risk for acute rejection, whereas a higher AUC 0-12h may lead to over-immunosuppression. Large between-subject variability (BSV) and time-dependent variation within-subjects are characteristics of MPA pharmacokinetics (PK) (Shaw et al., 2003; Le Meur et al., 2007; van Hest et al., 2007) . A 10-fold variation of MPA exposure was observed even in subjects administered the same dose during the first 2 weeks following kidney transplantation. Moreover, the MPA exposure in the early phase posttransplantation was 30-50% lower than that in the stable period when administered the same MMF dose (Shaw et al., 2003) .
The narrow therapeutic window and large PK variability make it necessary to individualize MMF therapy based on therapeutic drug monitoring. Currently, the maximum a posterior Bayesian method using population PK (popPK) in combination with Bayesian estimation is recommended for facilitating the optimal pharmacotherapy (Tobler and Muhlebach, 2013; Wright and Duffull, 2013; Zhao et al., 2016; Mao et al., 2018) . This approach is based on a comprehensive understanding of prior information, i.e., the popPK characteristics.
The popPK characteristics of total MPA (tMPA) in kidney transplant recipients have been extensively investigated in various ethnic populations. Regarding unbound MPA (uMPA), the pharmacologically active component, only a few investigations have used the population approach (de Winter et al., 2009; van Hest et al., 2009; Colom et al., 2018; Okour et al., 2018) because of the technical complexity of measurements. Furthermore, the information in Chinese kidney transplant recipients is limited. Therefore, the objectives of this study were to develop a popPK model to: (1) characterize the PK of uMPA, tMPA, and the main metabolite MPAG in Chinese kidney transplant patients cotreated with CsA, and (2) identify the clinically significant covariates that explain the variability in the dose-exposure relationship.
METHODS

Study Design and Patients
The data were obtained from two clinical studies (Jiao et al., 2007; Geng et al., 2012) . The inclusion criteria were as follows: patients 1) receiving first-time kidney transplantation; 2) administered triple immunosuppressive therapy comprising MMF (CellCept ® , Roche Pharma Ltd., Shanghai, China), CsA, and corticosteroids; 3) and aged over 18 years. The exclusion criteria were: 1) pregnant or lactating women; patients 2) with severe gastrointestinal disorders; 3) cotreated with cholestyramine; 4) and receiving combined organ transplantation.
The first study was an evaluation of the PK of MPA and MPAG during the early posttransplantation period conducted at Huashan Hospital, Fudan University (Jiao et al., 2007) . MMF was initiated at 1,500 mg/day from the day of surgery. The second study was an open-label, multicenter, two-phase, sequential, bioequivalence study conducted in stable kidney transplantation patients (Geng et al., 2012) . MMF dose was 1,000 or 1,500 mg/day in most patients. All protocols were approved by the independent Clinical Research Ethics Committee of Huashan Hospital, Fudan University, and all participants provided written informed consent before enrolment.
After the morning dose, whole blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 , and 12 h in study 1 and 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 10 , and 12 h in study 2. Low-fat meals were provided after the scheduled 4 and 10 h samplings in study 1 and the 3 and 9 h samplings in study 2. The relevant data were collected to explore the relationships between demographic characteristics, biochemical measurements, and PK parameters.
All samples were analyzed at Huashan Hospital using a validated high-performance liquid chromatography method (Jiao et al., 2005; Jiao et al., 2007) . The calibration ranges were 0.002-1.0, 0.1-40, and 10-200 mg/L for uMPA, tMPA, and total MPAG (tMPAG), respectively. The relative bias at lower limit of quantification (LLOQ) were within ±17% for uMPA, within ±8.3% for tMPA, and tMPAG. The relative bias of other quality control concentrations for uMPA, tMPA, and tMPAG was within ±6.1%. The intra-and interday precision, as coefficient of variation values, were <14% for uMPA, < 9.2% for tMPA, and <9.8% for tMPAG.
PopPK Analyses
Software and Model Selection Criteria
Nonlinear mixed-effect modeling was performed using NONMEM ® software (version 7.4; ICON Development Solutions, Ellicott City, MD, USA) compiled with gfortran 4.6.0. Perl-speaks-NONMEM (PsN, version 4.7.0; http:// uupharmacometrics.github.io/PsN) and Pirana (version 2.9.7; http://www.certara.com/pirana) were used to link NONMEM, model development, and model evaluation. The stochastic approximation expectation maximization (SAEM), followed by important sampling (IMP) method (Bauer, 2017) were used throughout the model development. Graphical diagnostics were performed using R software (version 3.4.4, http://www.rproject.org).
MMF doses and uMPA, tMPA, and tMPAG concentrations were transformed into molar equivalents by dividing them with the molecular weight (MMF, MPA, and MPAG: 433.498, 320.339, and 496 .462 g/mol, respectively; http://chem.nlm.nih.gov/chemidplus/) and then reconverted to milligram per liter in the figures and results. Model selection was based on goodness-of-fit (GOF) plots (Ette and Ludden, 1995) in addition to the three commonly used criteria of statistical significance, plausibility, and stability. The difference in objective function values (OFV) between two nested models was used for statistical comparison. Akaike information criteria (AIC) (Vaida and Blanchard, 2005) and Bayesian information criteria (BIC) (Delattre et al., 2012) were used to discriminate nonnested models.Additionally, relative standard errors (RSEs) of parameter estimates, shrinkages, and changes of BSV and residual unexplained variability (RUV) estimates were considered. During the model developing process, the condition numbers were calculated and no more than 1,000 were kept to avoid overparameterization (Owen and Fiedler-Kelly, 2014) .
Model Development
PopPK modeling of MPA and MPAG was conducted using a sequential approach and eventually led to simultaneous modeling of both the parent compound and metabolite. Oneor two-compartments models with first-order elimination were tested for uMPA and unbound MPAG (uMPAG). We further investigated whether MPA absorption was best described by a firstor zero-order process, with or without a lagged absorption time (Tlag). The concentrations of uMPAG were not determined in our study but were estimated from tMPAG by multiplying the unbound fraction of MPAG (FU MPAG ), which was fixed at 18% according to the U.S. Food and Drug Administration (FDA) package insert for CellCept ® (FDA, 2019).
The tMPA data was first modeled by adding a linear protein binding compartment as equation 1:
where C tMPA and C uMPA represent total and unbound MPA concentrations, respectively, and k B is the protein binding rate constant. In this case, the unbound fraction of MPA (FU MPA ) could be expressed as equation 2:
The nonlinear saturable protein binding model published previously (Picard-Hagen et al., 2001; Colom et al., 2018) was also evaluated using equation 3:
where C bMPA represents the bound MPA concentration, B max is the maximal number of protein binding sites, and k D is the dissociation constant representing the uMPA concentration corresponding to half-saturation of protein binding. To describe the physiological EHC process, the previously published intermittent EHC model (Jiao et al., 2008; Ling et al., 2015) was used with some modifications, in which a gallbladder compartment was introduced to connect MPAG and gut compartments. The percentage of MPAG recycled into the systemic circulation (%EHC) was described using equation 4:
where, k GG is the transfer rate constant from the MPAG central compartment to the gallbladder and k e0 is the elimination rate constant of MPAG. Several assumptions were made to ensure the model was structurally identifiable (Jiao et al., 2008) : (1) MMF is quickly absorbed and completely hydrolyzed to MPA, (2) the conversion ratio from MPA to MPAG is fixed at 87% (FDA, 2019), (3) MPAG secreted from the gallbladder to the intestines is completely deconjugated to MPA and reabsorbed, (4) the rate constants associated with each compartment are all first-order and unaffected by the recycling, and (5) gallbladder emptying is triggered by meals. Additionally, the gallbladder emptying rate constant (k GB ) was fixed at 3.708/h based on previous study (Guiastrennec et al., 2016) . The duration (D GB ) of gallbladder release was fixed at 0.5 h to ensure that over 90% gallbladder contents would be released after each trigger.
An exponential model was used to describe BSVs for each PK parameter while exponential, additive, and combined models were compared to describe RUVs. Furthermore, the covariance of BSVs was estimated using OMEGA BLOCK statement in NONMEM. Because uMPA, tMPA, and tMPAG concentrations were derived from the same sample for each subject, their RUVs were likely correlated. An L2 data item was introduced and the covariance of RUVs was also evaluated using SIGMA BLOCK statement (Bauer, 2017) . After the base model was established, the following physiologically meaningful covariates were investigated: sex, age, body weight (BW), postoperative time (POT), hemoglobin, ALB, alanine aminotransferase, aspartate aminotransferase, serum creatinine (SCr), glomerular filtration rate (GFR), CsA daily dose, and coadministration of antacids. GFR was estimated from SCr using the Chronic Kidney Disease Epidemiology Collaboration formula (Levey et al., 2009) .
First, relationships between individual PK parameters and covariates were examined by graphical inspection to identify the potential covariates. Then, the identified covariates were tested using a stepwise procedure. During the forward inclusion and backward elimination steps, significance levels were set at a decrease in OFV > 3.84 (c 2 , df = 1, p < 0.05) and an increase in OFV > 10.83 (c 2 , df = 1, p < 0.001), respectively. The continuous covariates were assessed using a linear and non-linear model, and categorical covariates were modeled proportionally. To demonstrate clinical significance, covariates were only retained if the effect on the corresponding parameter was >15% for a categorical covariate, or >15% at the highest or lowest observed covariate value for a continuous covariate (Mo et al., 2018) . In addition, the included covariates were expected to have interpretations of physiological or pharmacological mechanisms.
Model Evaluation
The established model was evaluated by graphical diagnosis. GOF plots included scatterplots of population predictions (PRED) and individual predictions (IPRED) versus observed concentrations (OBS), as well as conditional weighted residuals (CWRES) versus PRED and time after previous dose (TAD). Observations over ±4 CWRES based on final model were excluded from the original dataset, and the sensitivity analysis was performed to verify the model. Additionally, 500 bootstraps (Ette et al., 2003) were applied to assess the reliability and stability of the final model. The medians and 2.5-97.5% intervals from the bootstrap replicates were compared with estimates of the final model.
The final model was further examined using a predictioncorrected visual predictive check (pc-VPC) (Bergstrand et al., 2011) and posterior predictive check (PPC) (Yano et al., 2001) . Furthermore, 2,000 datasets were simulated using the final model from the original dataset. For pc-VPC, the observed and simulated concentrations were dose-normalized to 750 mg MMF every 12 h. The median, 5th and 95th percentiles of simulated concentrations and corresponding 95% confidence intervals (CIs) were calculated and graphically compared with the observations. PPC was further performed to assess if the model appropriately predicted the AUC 0-12h of uMPA, tMPA, and tMPAG. Simulated and observed AUC 0-12h were calculated using the linear trapezoidal rule. Distributions of the simulated and observed AUC 0-12h were then graphically compared.
Simulation Analyses of Effects of Significant Covariates
The established final model was used to investigate the effect of the identified covariates on the PK of MPA and MPAG. Specifically, 2,000 stochastic simulations were performed for virtual subjects administered 750 mg MMF every 12 h with different covariate levels. The AUC 0-12h values of uMPA, tMPA, and tMPAG were estimated using the linear trapezoidal rule, and changes in AUC 0-12h and FU MPA were assessed.
RESULTS
Patient Characteristics and Data Descriptions
A total of 27 full concentration-time profiles containing uMPA, tMPA, and tMPAG data were obtained from 20 patients in study 1, including 23 profiles collected within 3 months posttransplantation. Sixteen patients had one profile, one had two profiles, and the other three each had three profiles. In study 2, we obtained 38 full concentration-time profiles from 38 patients, including 37 collected beyond 3 months posttransplantation. The patient characteristics are shown in Table 1 . Of these subjects, male patients accounted for approximately 78%. The concomitant antacids in study 1 were proton pump inhibitors, whereas sodium hydrogen carbonate and compound aluminum hydroxide were coadministered in study 2. Significant differences in BW, POT, hemoglobin, and ALB as well as doses of MMF, CsA, and corticosteroids were observed between the two studies.
Of the 2,229 samples, < 1% (3 uMPA, 1 tMPA, and 10 tMPAG) were below the LLOQ and were discarded. In total, 740 uMPA, 741 tMPA, and 734 tMPAG concentration measurements were used for the popPK analysis. Multiple uMPA and tMPA peaks attributed to EHC were observed at 4-6 and 8-12 h postdosing in some subjects, whereas no obvious multiple peaks were observed for tMPAG. After being normalized to MMF 1,500 mg/day, the median AUC 0-12h of uMPA in study 2 was significantly higher than that in study 1 (38.60 vs. 27.21 mg·h/L). No significant differences in the AUC 0-12h of tMPA and tMPAG were found between the two studies.
PopPK Model
Model Development
As shown in Figure 1 , a five-compartment model with first-order absorption and elimination adequately described the uMPA, tMPA, and uMPAG data. The two-compartment (2CMT) structural model was superior to the one-compartment ( The PK parameters estimated were absorption rate constant (k a ), Tlag, apparent clearance (CL/F) of uMPA and uMPAG (CL uMPA /F and CL uMPAG /F, respectively), apparent intercompartmental clearance of uMPA (Q uMPA /F), apparent central volume of distribution (V C /F) of uMPA and uMPAG (V CuMPA /F and V CuMPAG /F, respectively), k B , and %EHC. Apparent peripheral volume of distribution of uMPA (V PuMPA /F) could not be estimated appropriately and was fixed at the reported literature value of 34,300 L (de Winter et al., 2009) .
Considering that the expectation maximization (EM) algorithm is much more robust and adept at handling the large full OMEGA block (Bauer, 2017) , we initially attempted to assign BSVs to all PK parameters. However, our data did not support the estimation of BSV on k B . To maximally enhance the EM efficiency, the BSV was assigned to k B , and its variance was fixed at 0.01 (Bauer, 2017) . Various RUV models were tested to describe the residual errors. Incorporation of the additive residual error resulted in boundary issues and therefore, an exponential RUV model was used.
Based on the visual inspections and clinical plausibility, the effects of BW and sex on CL uMPA /F, Q uMPA /F, V CuMPA /F, CL uMPAG /F, and V CuMPAG /F; GFR on k B , CL uMPA /F, Q uMPA /F, and CL uMPAG /F; ALB on k B , V CuMPA /F, and V CuMPAG /F; coadministration of antacids on CL uMPA /F and k a ; and tMPAG concentrations on k B were further tested using the stepwise method. Of these, the effects of ALB on k B , GFR on CL uMPAG /F, and BW and sex on Q uMPA /F were included in the forward procedure, whereas the effect of sex on Q uMPA /F showed no significance in the backward step and, thus, was not retained in the final model. The forward inclusion and backward elimination steps are summarized in Supplementary Table 1 . Because the estimated value of the exponent for the effect of ALB on k B was quite close to 1, it was fixed at 1 to simplify the model and maintain the model stability.
Although introduction of full variance-covariance matrices for BSVs and RUVs substantially decreased the OFV by 262.265 units, the high condition number (7.5 × 10 10 ) indicated that the model might be ill-conditioned because of overparameterization. Finally, the covariance between BSVs for V CuMPAG /F and CL uMPAG /F and between RUVs for uMPA and tMPA was included. This further decreased the OFV by 163.434 units with an acceptable condition number (< 150). The parameter estimates of the final model are provided in Table 2 . No significant covariate was detected to influence CL uMPA /F, whereas significant relationships were found between k B and ALB and between CL uMPAG /F and GFR. RSEs of the parameter estimates were <30 and 45% for fixed and random effects except for %EHC, respectively. Shrinkage values of BSVs and RUVs were <30% except for %EHC.
Model Evaluation
The basic GOF plots of the final model are shown in Figure 2 where PRED and IPRED did not show obvious bias when plotted against Table 2 ). The GOFs and sensitivity analysis results showed that the model adequately described the data despite the fact that a slightly positive bias could be found in the residual plots. Out of 500 replicates in the bootstrap analysis, all runs converged successfully. The estimated parameters based on original dataset were in good agreement with the median bootstrap replicates and were within the 2.5-97.5% intervals obtained from the bootstrap analysis (Table 2) , indicating the reliability and stability of the final model. Figure 3 shows the results of the pc-VPC of the final model. Most observed concentrations fell within the 90% prediction interval, and no obvious discrepancy between observations and simulations was found. The PPC suggested that the simulated AUC 0-12h values also showed good consistency with the observations (Figure 4) . The pc-VPC and PPC results showed that the final model was reasonably good at predicting the observations.
Simulations Illustrating Effect of Covariates
Typical subjects administered 750 mg MMF every 12 h were simulated with different ALB and GFR levels. ALB values were set from 20 to 50 g/L with a step of 5 g/L. At each ALB level, the GFR was set at 15, 30, 60, 90, and 120 mL/min according to the Kidney Disease Improving Global Outcomes (KIDGO) chronic kidney disease classification (Kidney Disease: Improving Global Outcomes CKD Work Group, 2013). Generally, ALB and GFR showed large effects on tMPA and tMPAG, respectively, but little effect on uMPA ( Figure 5) .
A substantial decrease in tMPA AUC 0-12h and increase in FU MPA were observed with decreasing ALB concentrations. For subjects with a GFR of 90 mL/min administered 750 mg MMF every 12 h, the median tMPA AUC 0-12h decreased from 42.92 to 21.59 mg·h/L when ALB concentrations decreased from 40 to 20 g/ L, whereas the exposure of uMPA and tMPAG remained almost unchanged (< 5%). A decrease in ALB concentrations from 40 to 20 g/L increased FU MPA from 1.86% (95% CI, 1.35-2.58%) to 3.62% (95% CI, 2.62-5.02%) ( Supplementary Figure 1) .
Additionally, a substantial increase in tMPAG AUC 0-12h was observed with decreasing GFR. For subjects with an ALB concentration of 40 g/L administered 750 mg MMF every 12 h, a reduction in GFR from 90 to 15 mL/min led to a 3.67-fold (95% CI, 3.13-4.30) increase in tMPAG AUC 0-12h , while FU MPA and the exposure of both uMPA and tMPA were unchanged ( Figure 5 and Supplementary Figure 1) . The simulations showed that neither ALB nor GFR significantly affected uMPA exposure. For patients with lower ALB levels, dose adjustment based on monitoring tMPA would lead to higher risk of leucopoenia and infections, because of overexposure to uMPA.
DISCUSSION
The present study extensively investigated the popPK characteristics of uMPA, tMPA, and MPAG in Chinese adult kidney transplant recipients cotreated with CsA during both the early and stable periods posttransplantation. A two-compartment model with firstorder absorption and elimination adequately described the uMPA data. Furthermore, the uMPA and tMPA were connected using a linear protein binding model.
It is still controversial whether ethnic differences exist in MPA PK. Some studies have reported higher dose-normalized AUCs of MPA in Asian subjects than in Caucasians (Lu et al., 2005; Zicheng et al., 2006; Yau et al., 2007; Zhou et al., 2007; Miura et al., 2009 ). Li et al. (2014) reported that Asians had lower MPA CL/F and required lower MMF doses than Caucasians did. This could be partly explained by the significantly lower BW of Asian subjects. CL tMPA /F, CL tMPAG /F, CL uMPA /F and CL uMPAG /F, apparent clearance of tMPA, tMPAG, uMPA and uMPAG, respectively; GFR, glomerular filtration rate; k a , absorption rate constant; k B , protein binding rate constant; Q tMPA /F and Q uMPA /F, apparent intercompartmental clearance of tMPA and uMPA, respectively; Tlag, lagged absorption time; V CtMPA /F, V CtMPAG /F, V CuMPA / F and V CuMPAG /F, apparent central volume of distribution of tMPA, tMPAG, uMPA and uMPAG, respectively; V PtMPA /F, apparent peripheral volume of distribution of tMPA. a %RSE is estimated as the standard error of the estimate divided by the population estimate multiplied by 100. After correcting for BW, the average tMPA CL/F (CL tMPA /F) of Asians and Caucasians was close (POT ≤ 6 months: 0.35 vs. 0.36 L/h/kg; POT > 6 months: 0.22 vs. 0.25 L/h/kg) following coadministration of CsA (Li et al., 2014) . In contrast, several studies showed that MPA PK in Asians was similar to that in Caucasians (Funaki, 1999; Cho et al., 2004; Jiao et al., 2007; Ling et al., 2015) . In addition, our previous study suggested that the lower dose required in Chinese patients than in Caucasians could result in comparable inhibitory rates of inosine-5′monophosphate dehydrogenase (24-42%) (Liu et al., 2018) . The difference in dose requirement might not be attributable to PK but to pharmacodynamics.
The current study showed no obvious ethnic difference in exposure of uMPA. As shown in Table 3 , the population estimate of BW corrected-CL uMPA /F (13.95 L/h/kg) was comparable to most of previously reported values in Caucasians (9.21-12.93 L/h/kg) (de Winter et al., 2009; van Hest et al., 2009; Colom et al., 2018) . Moreover, the typical value of BW corrected-CL tMPA /F (0.26 L/h/kg) was also similar to most of previously reported values in Asians (0.21-0.32 L/h/kg) (Yau et al., 2009; Yu et al., 2017; Chen et al., 2019) and Caucasians (0.18-0.32 L/h/kg) (Le Guellec et al., 2004; Cremers et al., 2005; Staatz et al., 2005; van Hest et al., 2007; de Winter et al., 2008; Musuamba et al., 2009; Guillet et al., 2010; de Winter et al., 2012; Colom et al., 2014) . Furthermore, the population estimate of FU MPA in our study (1.84%) was also similar to previously reported values Colom et al., 2018) .
The stepwise covariate analyses suggested that ALB had significant effects on k B and FU MPA . MPA is extensively bound to human ALB, which has more than one binding site on each molecule with equivalent binding characteristics (Nowak and Shaw, 1995) . A reduction in ALB decreases the binding sites, which increases the FU MPA . The simulations showed that changes in ALB concentrations substantially affected FU MPA and tMPA exposure, but had little effect on uMPA exposure, which was consistent with previous findings (de Winter et al., 2009; van Hest et al., 2009 ). This could be attributed to the low FIGURE 3 | Prediction-corrected visual predictive check plots of final model for uMPA, tMPA and tMPAG. Blue dots represent the observed concentrations. Red solid lines represent the median of observations, and the semitransparent red fields represent the simulation-based 95% CIs for the median. The observed 5th and 95th percentiles are presented with red dashed lines, and the simulation-based 95% CIs for corresponding percentiles are shown as semitransparent blue fields. In general, the median, and 5th and 95th percentile lines of observations fall inside the area of the corresponding 95% CIs. Additionally, the majority of observed concentrations fall within the 90% prediction interval, which demonstrates that the predicted variability does not exceed the observed variability. CIs, confidence intervals; tMPA, total mycophenolic acid (MPA); tMPAG, total 7-O-mycophenolic acid glucuronide; uMPA, unbound MPA.
FIGURE 4 | Posterior predictive check graphics of final model for uMPA, tMPA, and tMPAG. The histograms represent the distribution of simulations. Black and blue solid lines represent the medians of observations and simulations, respectively. The observed 5th and 95th percentiles are presented by black dashed lines, and the simulated 5th and 95th percentiles are presented by blue dashed lines. The simulated AUC 0-12h values present good consistency with observations. In particular, the 5th percentiles of simulations and observations for uMPA, as well as the medians of simulations and observations for tMPAG, are completely overlapped in the graphics. AUC 0-12h , area under the concentration-time curve within 12-h dose-interval; tMPA, total mycophenolic acid (MPA); tMPAG, total 7-O-mycophenolic acid glucuronide; uMPA, unbound MPA. 
References
Present study Okour et al., 2018 Colom et al., 2018 van Hest et al., 2009 de Winter et al., 2009 Number hepatic extraction ratio of MPA. FU MPA tended to increase with decreasing ALB (Supplementary Figure 1 ) and the increase in FU MPA caused relatively more uMPA to be metabolized and eliminated from the body, thereby decreasing tMPA exposure. In contrast, MPA is characterized by a low hepatic extraction ratio of 0.2 (Bowalgaha and Miners, 2001) , and the unbound exposure of drugs with low extraction ratio is unaffected by changes in the unbound fraction (Benet and Hoener, 2002) . These results suggested that dose adjustment based on tMPA exposure might not be appropriate under lower ALB conditions. A reduction in median tMPA AUC 0-12h from approximately 42.9 to 21.6 mg·h/L was observed when ALB concentration decreased from 40 to 20 g/L for patients administered 750 mg MMF every 12 h. However, this observation does not indicate an MMF dose increment is necessary because of the unchanged uMPA exposure. Although a relationship between uMPA exposure and acute rejection risk has not been fully identified, uMPA has been recognized as the pharmacologically active component. Moreover, uMPA exposure has been demonstrated to be associated with the risk of leucopoenia and infections (Kaplan et al., 1998; Weber et al., 2002; Mudge et al., 2004; Atcheson et al., 2005) . An increased MMF dose would also increase uMPA exposure, placing patients at a higher risk of overimmunosuppression with manifestations such as leucopoenia and infections. In such situations, monitoring uMPA exposure might be preferable to monitoring tMPA for adjusting the MMF dose.
Moreover, it has been reported that tMPA exposure in the early phase post-transplantation was 30-50% lower than that in the stable period when the same MMF dose was administered (Shaw et al., 2003) . This time-dependent clearance could be largely attributed to changes in protein binding, resulted by increasing GFR, ALB, and hemoglobin levels with extension of time after transplantation (van Hest et al., 2007) . In the present study, the influence of POT was reflected in corresponding changes in ALB concentrations, which significantly impacted FU MPA . Alterations of protein binding had little effect on uMPA PK because of the low extraction ratio (Bowalgaha and Miners, 2001; Benet and Hoener, 2002) . In addition, the significant positive association between Q uMPA /F and BW was observed in the present study. This relationship is consistent with the known physiological properties.
Additionally, a gallbladder compartment was introduced to characterize the intermittent EHC process in the current popPK analysis. Generally, the intermittent gallbladder emptying process is considered to be triggered by ingestion of food (Ghibellini et al., 2006) . The EHC process is mediated by multidrug resistance-associated protein 2, which is inhibited by CsA (Hesselink et al., 2005) . All subjects in our study were cotreated with CsA. Meal time was set at 10 (study 1) and 9 (study 2) h postdosing, and the samplings before and after food intake were considered in the study protocol. The EHC triggered by food intake was applied during modeling. Nevertheless, the secondary peaks were not pronounced due to the inhibitory effect of CsA. Therefore, inhibition of EHC by CsA might likely explain why the final model estimated an extremely low %EHC with a high shrinkage (> 50%).
Regarding the metabolite MPAG, a statistically significant relationship was found between CL uMPAG /F and kidney function, which was consistent with findings of previous studies (de Winter et al., 2009; Musuamba et al., 2009; van Hest et al., 2009; Colom et al., 2014) . A reduction in GFR from 90 to 15 mL/ min led to a 3.67-fold increase in MPAG exposure. This could be because MPAG is primarily eliminated by the kidney through passive glomerular filtration and active tubular secretion (Bullingham et al., 1998) .
Nevertheless, the previously reported competitive protein binding relationship between MPA and MPAG (de Winter et al., 2009; van Hest et al., 2009) was not observed, which might be associated with the relatively lower MPAG concentrations (median, 49.79 mg/L). Only 7.6% (56/734) of the tMPAG concentrations were >100 mg/L with a maximum of 177.9 mg/L in our study. At high concentrations, MPAG could displace MPA from its protein binding sites. It has been reported in vitro that FU MPA increased threefold as the MPAG concentration increased from 0 to 800 mg/L (Nowak and Shaw, 1995) .
There are some limitations in the present study. Firstly, uMPAG concentrations were not determined and FU MPAG was fixed at 18%. The effect of ALB alteration on MPAG binding could not be investigated. MPAG is pharmacologically inactive and did not show significant influence on MPA PK in our analysis because of the relatively lower MPAG concentrations. Secondly, only one dose level of MMF was administered to most patients, which prevented us from investigating the reported nonlinear relationship between MMF dose and MPA exposure (de Winter et al., 2011) . Lastly, all patients in our study were coadministered MMF and CsA, whereas TAC and CsA are well known to influence the EHC process differently. Therefore, our results might only be applicable to patients cotreated with CsA.
CONCLUSIONS
In summary, the established model adequately described the popPK characteristics of uMPA, tMPA, and MPAG. Large BSVs and RUVs were still observed, suggesting therapeutic drug monitoring would be necessary for optimization of MMF therapy. The estimated CL uMPA /F and FU MPA in Chinese kidney transplant recipients were comparable to those published previously in Caucasians. In addition, tMPA exposure reduced with decreasing ALB, which had little effect on uMPA exposure. Therefore, under lower ALB conditions, dose adjustment based on tMPA exposure might place patients at higher risk of overimmunosuppression. We recommend monitoring uMPA instead of tMPA to optimize MMF dosing for patients with lower ALB concentrations.
